{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T15:12:56Z","timestamp":1771081976716,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Ther Perspect"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40267-023-01000-5","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T09:02:46Z","timestamp":1686906166000},"page":"249-261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["All-round approaches to increase adverse drug reaction reports: a scoping review"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9979-0062","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Joaquim","sequence":"first","affiliation":[]},{"given":"Cristiano","family":"Matos","sequence":"additional","affiliation":[]},{"given":"Diana","family":"Guerra","sequence":"additional","affiliation":[]},{"given":"Ramona","family":"Mateos-Campos","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"issue":"1","key":"1000_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40360-020-00464-9","volume":"21","author":"S-D Woo","year":"2020","unstructured":"Woo S-D, Yoon J, Doo G-E, et al. Common causes and characteristics of adverse drug reactions in older adults: a retrospective study. BMC Pharmacol Toxicol. 2020;21(1):87.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"1","key":"1000_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/1472-6963-10-287","volume":"10","author":"P Carrasco-Garrido","year":"2010","unstructured":"Carrasco-Garrido P, de Andr\u00e9s LA, Barrera VH, et al. Trends of adverse drug reactions related-hospitalizations in Spain (2001\u20132006). BMC Health Serv Res. 2010;10(1):287.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"1000_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1472-6963-14-73","volume":"14","author":"S Qing-ping","year":"2014","unstructured":"Qing-ping S, Xiao-dong J, Feng D, et al. Consequences, measurement, and evaluation of the costs associated with adverse drug reactions among hospitalized patients in China. BMC Health Serv Res. 2014;14(1):73.","journal-title":"BMC Health Serv Res"},{"key":"1000_CR4","doi-asserted-by":"publisher","first-page":"baac071","DOI":"10.1093\/database\/baac071","volume":"2022","author":"G Gonzalez-Hernandez","year":"2022","unstructured":"Gonzalez-Hernandez G, Krallinger M, Mu\u00f1oz M, et al. Challenges and opportunities for mining adverse drug reactions: perspectives from pharma, regulatory agencies, healthcare providers and consumers. Database. 2022;2022:baac071.","journal-title":"Database"},{"key":"1000_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s40267-016-0355-9","volume":"33","author":"C Matos","year":"2017","unstructured":"Matos C, Joaquim J, Pires T. Attitudes and knowledge of community pharmacy professionals regarding the spontaneous reporting of adverse drug reactions: a preliminary study in Coimbra, Portugal. Drugs Ther Perspect. 2017;33:88\u201394.","journal-title":"Drugs Ther Perspect."},{"key":"1000_CR6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s40267-017-0380-3","volume":"33","author":"C Matos","year":"2017","unstructured":"Matos C, Rodrigues L, Joaquim J. Attitudes and opinions of Portuguese community pharmacy professionals towards patient reporting of adverse drug reactions and the pharmacovigilance system. Drugs Ther Perspect. 2017;33:188\u201394.","journal-title":"Drugs Ther Perspect."},{"key":"1000_CR7","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40264-018-0748-x","volume":"42","author":"C Matos","year":"2019","unstructured":"Matos C, Weits G, van Hunsel F. The role of European patient organizations in pharmacovigilance. Drug Saf. 2019;42:547\u201357.","journal-title":"Drug Saf"},{"key":"1000_CR8","doi-asserted-by":"publisher","first-page":"204209862095393","DOI":"10.1177\/2042098620953935","volume":"11","author":"C Matos","year":"2020","unstructured":"Matos C, van Hunsel F, Tavares Ribeiro R, et al. Diabetes patient\u2019s pharmacovigilance knowledge and risk perception: the influence of being part of a patient organisation. Ther Adv Drug Saf. 2020;11:2042098620953935.","journal-title":"Ther Adv Drug Saf."},{"issue":"5","key":"1000_CR9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.7861\/clinmedicine.16-5-481","volume":"16","author":"JJ Coleman","year":"2016","unstructured":"Coleman JJ, Pontefract SK. Adverse drug reactions. Clin Med. 2016;16(5):481.","journal-title":"Clin Med"},{"issue":"3","key":"1000_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.4103\/0975-1483.66802","volume":"2","author":"G Jeetu","year":"2010","unstructured":"Jeetu G, Anusha G. Pharmacovigilance: a worldwide master key for drug safety monitoring. J Young Pharm. 2010;2(3):315\u201320.","journal-title":"J Young Pharm"},{"issue":"12","key":"1000_CR11","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/j.clinthera.2018.07.012","volume":"40","author":"P Beninger","year":"2018","unstructured":"Beninger P. Pharmacovigilance: an overview. Clin Ther. 2018;40(12):1991\u20132004.","journal-title":"Clin Ther"},{"issue":"5","key":"1000_CR12","first-page":"1180","volume":"28","author":"M Lindquist","year":"2001","unstructured":"Lindquist M, Edwards IR. The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring Center. J Rheum. 2001;28(5):1180.","journal-title":"J Rheum"},{"issue":"5","key":"1000_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M. VigiBase, the WHO Global ICSR Database System: basic facts. Drug Inf J. 2008;42(5):409\u201319.","journal-title":"Drug Inf J"},{"issue":"3","key":"1000_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/pds.4381","volume":"27","author":"X Kurz","year":"2018","unstructured":"Kurz X, Perez-Gutthann S, the ESG. Strengthening standards, transparency, and collaboration to support medicine evaluation: ten years of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Pharmacoepidemiol Drug Saf. 2018;27(3):245\u201352.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"1000_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/pharmacy11010010","volume":"11","author":"MA Khan","year":"2023","unstructured":"Khan MA, Hamid S, Babar Z-U-D. Pharmacovigilance in high-income countries: current developments and a review of literature. Pharmacy [Internet]. 2023;11(1):10.","journal-title":"Pharmacy [Internet]."},{"issue":"7","key":"1000_CR16","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s00228-015-1867-2","volume":"71","author":"C Matos","year":"2015","unstructured":"Matos C, van Hunsel F, Joaquim J. Are consumers ready to take part in the Pharmacovigilance System? A Portuguese preliminary study concerning ADR reporting. Eur J Clin Pharmacol. 2015;71(7):883\u201390.","journal-title":"Eur J Clin Pharmacol"},{"key":"1000_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40264-020-00999-0","volume":"44","author":"K Chinchilla","year":"2021","unstructured":"Chinchilla K, Matos C, Hall V, et al. Patient organizations\u2019 barriers in pharmacovigilance and strategies to stimulate their participation. Drug Saf. 2021;44:181\u201391.","journal-title":"Drug Saf"},{"issue":"10","key":"1000_CR18","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s40264-022-01222-y","volume":"45","author":"M van Hoof","year":"2022","unstructured":"van Hoof M, Chinchilla K, H\u00e4rmark L, et al. Factors contributing to best practices for patient involvement in pharmacovigilance in Europe: a stakeholder analysis. Drug Saf. 2022;45(10):1083\u201398.","journal-title":"Drug Saf"},{"issue":"1","key":"1000_CR19","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1186\/s12913-019-4775-9","volume":"19","author":"R Adisa","year":"2019","unstructured":"Adisa R, Omitogun TI. Awareness, knowledge, attitude and practice of adverse drug reaction reporting among health workers and patients in selected primary healthcare centres in Ibadan, southwestern Nigeria. BMC Health Serv Res. 2019;19(1):926.","journal-title":"BMC Health Serv Res"},{"key":"1000_CR20","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40264-016-0453-6","volume":"39","author":"C Matos","year":"2016","unstructured":"Matos C, H\u00e4rmark L, van Hunsel F. Patient reporting of adverse drug reactions: an international survey of national competent authorities\u2019 views and needs. Drug Saf. 2016;39:1105\u201316.","journal-title":"Drug Saf"},{"issue":"12","key":"1000_CR21","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40264-018-0708-5","volume":"41","author":"A Radecka","year":"2018","unstructured":"Radecka A, Loughlin L, Foy M, et al. Enhancing pharmacovigilance capabilities in the EU regulatory network: the SCOPE joint action. Drug Saf. 2018;41(12):1285\u2013302.","journal-title":"Drug Saf"},{"issue":"5","key":"1000_CR22","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/j.1365-2125.2011.03990.x","volume":"72","author":"C Anderson","year":"2011","unstructured":"Anderson C, Krska J, Murphy E, et al. The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective. Brit J Clin Pharmacol. 2011;72(5):806\u201322.","journal-title":"Brit J Clin Pharmacol."},{"issue":"6","key":"1000_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40264-014-0162-y","volume":"37","author":"F Margraff","year":"2014","unstructured":"Margraff F, Bertram D. Adverse Drug reaction reporting by patients: an overview of fifty countries. Drug Saf. 2014;37(6):409\u201319.","journal-title":"Drug Saf"},{"issue":"9","key":"1000_CR24","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s40264-016-0426-9","volume":"39","author":"MY Smith","year":"2016","unstructured":"Smith MY, Benattia I. The patient\u2019s voice in pharmacovigilance: pragmatic approaches to building a patient-centric drug safety crganization. Drug Saf. 2016;39(9):779\u201385.","journal-title":"Drug Saf"},{"issue":"11","key":"1000_CR25","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40264-016-0453-6","volume":"39","author":"C Matos","year":"2016","unstructured":"Matos C, H\u00e4rmark L, van Hunsel F. Patient reporting of adverse drug reactions: an international survey of national competent authorities\u2019 views and needs. Drug Saf. 2016;39(11):1105\u201316.","journal-title":"Drug Saf"},{"issue":"6","key":"1000_CR26","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/jep.12780","volume":"23","author":"F Chang","year":"2017","unstructured":"Chang F, Xi Y, Zhao J, et al. A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. J Eval Clin Pract. 2017;23(6):1316\u201321.","journal-title":"J Eval Clin Pract"},{"issue":"5","key":"1000_CR27","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s40264-017-0630-2","volume":"41","author":"F Montastruc","year":"2018","unstructured":"Montastruc F, Bagheri H, Lacroix I, et al. Adverse drug reaction reports received through the mobile app, VigiBIP\u00ae: a comparison with classical methods of reporting. Drug Saf. 2018;41(5):511\u20134.","journal-title":"Drug Saf"},{"issue":"5","key":"1000_CR28","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1365-2125.2009.03400.x","volume":"67","author":"F Van Hunsel","year":"2009","unstructured":"Van Hunsel F, Passier A, Van Grootheest K. Comparing patients\u2019 and healthcare professionals\u2019 ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example. Brit J Clin Pharmacol. 2009;67(5):558\u201364.","journal-title":"Brit J Clin Pharmacol."},{"issue":"12","key":"1000_CR29","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40264-018-0699-2","volume":"41","author":"O Caster","year":"2018","unstructured":"Caster O, Dietrich J, K\u00fcrzinger M-L, et al. Assessment of the utility of social media for broad-ranging statistical signal detection in pharmacovigilance: results from the WEB-RADR project. Drug Saf. 2018;41(12):1355\u201369.","journal-title":"Drug Saf"},{"issue":"1","key":"1000_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Method. 2005;8(1):19\u201332.","journal-title":"Int J Soc Res Method"},{"key":"1000_CR31","doi-asserted-by":"crossref","unstructured":"Peters MD, Godfrey C, McInerney P, et al. Chapter 11: scoping reviews. Joanna Briggs Institute reviewer\u2019s manual. 2020;169(7):467\u201373.","DOI":"10.46658\/JBIRM-20-01"},{"issue":"3","key":"1000_CR32","first-page":"141","volume":"13","author":"MDJ Peters","year":"2015","unstructured":"Peters MDJ, Godfrey CM, Khalil H, et al. Guidance for conducting systematic scoping reviews. JBI Evid Implement. 2015;13(3):141\u20136.","journal-title":"JBI Evid Implement"},{"issue":"7","key":"1000_CR33","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for coping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373.","journal-title":"Ann Intern Med"},{"issue":"5","key":"1000_CR34","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00228-005-0072-0","volume":"62","author":"M B\u00e4ckstr\u00f6m","year":"2006","unstructured":"B\u00e4ckstr\u00f6m M, Mj\u00f6rndal T. A small economic inducement to stimulate increased reporting of adverse drug reactions\u2014a way of dealing with an old problem? Eur J Clin Pharmacol. 2006;62(5):381\u20135.","journal-title":"Eur J Clin Pharmacol"},{"key":"1000_CR35","first-page":"39","volume":"17","author":"A Bhatia","year":"2005","unstructured":"Bhatia A, Kapoor U, Tayal G. A survey of issues regarding ADR and ADR reporting amongst doctors in Delhi. Int J Risk Saf Med. 2005;17:39\u201346.","journal-title":"Int J Risk Saf Med"},{"issue":"9","key":"1000_CR36","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/pds.4966","volume":"29","author":"M Khalili","year":"2020","unstructured":"Khalili M, Mesgarpour B, Sharifi H, et al. Interventions to improve adverse drug reaction reporting: a scoping review. Pharmacoepidemiol Drug Saf. 2020;29(9):965\u201392.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"1000_CR37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40264-014-0256-6","volume":"38","author":"E Lopez-Gonzalez","year":"2015","unstructured":"Lopez-Gonzalez E, Herdeiro MT, Pi\u00f1eiro-Lamas M, et al. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Saf. 2015;38(2):189\u201396.","journal-title":"Drug Saf"},{"issue":"5","key":"1000_CR38","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00228-008-0603-6","volume":"65","author":"M-L Johansson","year":"2009","unstructured":"Johansson M-L, Brunl\u00f6f G, Edward C, et al. Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports. Eur J Clin Pharmacol. 2009;65(5):511\u20134.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1000_CR39","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2165\/00002018-200831040-00007","volume":"31","author":"MT Herdeiro","year":"2008","unstructured":"Herdeiro MT, Pol\u00f3nia J, Gestal-Otero JJ, et al. Improving the reporting of adverse drug reactions. Drug Saf. 2008;31(4):335\u201344.","journal-title":"Drug Saf"},{"key":"1000_CR40","unstructured":"Uppsala Monitoring Centre. The quest for evidence. 2017. https:\/\/who-umc.org\/. Accessed 6 May 2023."},{"key":"1000_CR41","unstructured":"Santoro F, Norgela G. Joining forces on social media to raise ADR awareness. 2019. https:\/\/who-umc.org\/. Accessed 6 May 2023."},{"issue":"8","key":"1000_CR42","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40264-016-0422-0","volume":"39","author":"L Rolfes","year":"2016","unstructured":"Rolfes L, van Hunsel F, Taxis K, et al. The Impact of Experiencing adverse drug reactions on the patient\u2019s quality of life: a retrospective cross-sectional study in the Netherlands. Drug Saf. 2016;39(8):769\u201376.","journal-title":"Drug Saf"},{"key":"1000_CR43","unstructured":"Uppsala Monitoring Centre. Mapping the herbal jungle. 2018. https:\/\/who-umc.org\/. Accessed 6 May 2023."},{"key":"1000_CR44","unstructured":"Taavola H, Caster O, Tregunno PM, et al. Characteristics and Quality of Spontaneous ADR Reports Submitted via the WEB-RADR App. 2017. https:\/\/who-umc.org\/. Accessed 6 May 2023."},{"key":"1000_CR45","unstructured":"Gattepaille LM, Vidlin SH, Bergvall T, et al. Adverse event recognition in Twitter: results from the WEB-RADR consortium. 2018. https:\/\/who-umc.org\/. Accessed 6 May 2023."},{"key":"1000_CR46","unstructured":"WEB-RADR. Recognising Adverse Drug Reactions. 2020."},{"key":"1000_CR47","unstructured":"Uppsala Monitoring Centre. Finding cause dispositions and evidence-based medicine. 2020. https:\/\/who-umc.org\/. Accessed 6 May 2023."},{"key":"1000_CR48","unstructured":"HALMED. News And Educations 2020 https:\/\/www.halmed.hr\/. Accessed 6 May 2023."},{"key":"1000_CR49","unstructured":"The Medicines and Healthcare products Regulatory Agency. Help make medicines safer: report suspected side effects in children and during pregnancy 2018 https:\/\/www.gov.uk\/. Accessed 6 May 2023."},{"key":"1000_CR50","unstructured":"WEB-RADR. Innovative Medicines Initiative 2020. https:\/\/www.imi.europa.eu\/projects-results\/project-factsheets\/web-radr. Accessed 6 May 2023."},{"issue":"12","key":"1000_CR51","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1080\/14740338.2019.1669559","volume":"18","author":"B O\u2019Donovan","year":"2019","unstructured":"O\u2019Donovan B, Rodgers RM, Cox AR, et al. Making medicines safer: analysis of patient reports to the UK\u2019s Yellow Card Scheme. Expert Opin Drug Saf. 2019;18(12):1237\u201343.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"1000_CR52","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2165\/11590110-000000000-00000","volume":"34","author":"MZ Knezevic","year":"2011","unstructured":"Knezevic MZ, Bivolarevic IC, Peric TS, et al. Using facebook to increase spontaneous reporting of adverse drug reactions. Drug Saf. 2011;34(4):351\u20132.","journal-title":"Drug Saf"},{"issue":"4","key":"1000_CR53","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40264-016-0491-0","volume":"40","author":"CE Pierce","year":"2017","unstructured":"Pierce CE, Bouri K, Pamer C, et al. Evaluation of facebook and twitter monitoring to detect safety signals for medical products: an analysis of recent fda safety alerts. Drug Saf. 2017;40(4):317\u201331.","journal-title":"Drug Saf"},{"issue":"5","key":"1000_CR54","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40264-020-00912-9","volume":"43","author":"J Dietrich","year":"2020","unstructured":"Dietrich J, Gattepaille LM, Grum BA, et al. Adverse events in twitter-development of a benchmark reference dataset: results from IMI WEB-RADR. Drug Saf. 2020;43(5):467\u201378.","journal-title":"Drug Saf"},{"key":"1000_CR55","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s40264-019-00858-7","volume":"42","author":"J van Stekelenborg","year":"2019","unstructured":"van Stekelenborg J, Ellenius J, Maskell S, et al. Recommendations for the use of social media in pharmacovigilance: lessons from IMI WEB-RADR. Drug Saf. 2019;42:1393\u2013407.","journal-title":"Drug Saf"},{"key":"1000_CR56","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40264-019-00813-6","volume":"42","author":"CE Pierce","year":"2019","unstructured":"Pierce CE, de Vries ST, Bodin-Parssinen S, et al. Recommendations on the use of mobile applications for the collection and communication of pharmaceutical product safety information: lessons from IMI WEB-RADR. Drug Saf. 2019;42:477\u201389.","journal-title":"Drug Saf"},{"key":"1000_CR57","unstructured":"Uppsala Reports. Do drugs have a \u201cpuberty?\u201d. 2017. https:\/\/view.publitas.com\/uppsala-monitoring-centre\/uppsalareports75-web_new\/page\/1. Accessed 6 May 2023."},{"key":"1000_CR58","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40264-021-01042-6","volume":"44","author":"A Bulcock","year":"2021","unstructured":"Bulcock A, Hassan L, Giles S, et al. Public perspectives of using social media data to improve adverse drug reaction reporting: a mixed-methods study. Drug Saf. 2021;44:553\u201364.","journal-title":"Drug Saf"},{"issue":"8","key":"1000_CR59","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.3390\/ijerph18083862","volume":"18","author":"LM Kassem","year":"2021","unstructured":"Kassem LM, Alhabib B, Alzunaydi K, et al. Understanding patient needs regarding adverse drug reaction reporting smartphone applications: a qualitative insight from Saudi Arabia. Int J Environ Res Public Health. 2021;18(8):3862.","journal-title":"Int J Environ Res Public Health"},{"key":"1000_CR60","doi-asserted-by":"crossref","unstructured":"18th ISoP Annual Meeting \u201cPharmacovigilance without borders\u201d Geneva, Switzerland, 11\u201314 November, 2018. Drug Saf. 2018;41(11):1103\u2013273.","DOI":"10.1007\/s40264-018-0719-2"},{"key":"1000_CR61","unstructured":"Taavola H, Caster O, Tregunno PM, et al. Characteristics and Quality of Spontaneous ADR Reports Submitted via WEB-RADR App. https:\/\/who-umc.org\/media\/164440\/webradr_small.pdf. Accessed 6 May 2023."}],"container-title":["Drugs & Therapy Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40267-023-01000-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40267-023-01000-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40267-023-01000-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T10:27:07Z","timestamp":1689244027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40267-023-01000-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":61,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1000"],"URL":"https:\/\/doi.org\/10.1007\/s40267-023-01000-5","relation":{},"ISSN":["1172-0360","1179-1977"],"issn-type":[{"value":"1172-0360","type":"print"},{"value":"1179-1977","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"assertion":[{"value":"14 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jo\u00e3o Joaquim, Cristiano Matos, Diana Guerra, and Ramona Mateos-Campos declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualisation: JJ and CM. Methodology: JJ, CM and RM-C. Writing \u2013 original draft preparation: JJ. Writing \u2013 review and editing: JJ, CM, DG and RM-C. All authors have read and agreed to the published version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}